Ten years ago, a consensus report on the optimization of tacrolimus was published in this
journal. In 2017, the Immunosuppressive Drugs Scientific Committee of the International …

ABSTRACT Introduction: Tacrolimus (Tac) is the cornerstone of immunosuppressive therapy
after solid organ transplantation and will probably remain so. Excluding belatacept, no new …

The aim of this work is to estimate the area‐under the blood concentration curve of
tacrolimus (TAC) following bid or qd dosing in organ transplant patients, using Xgboost …

Abstract Background and Objectives Numerous population pharmacokinetic (PK) models of
tacrolimus in adult transplant recipients have been published to characterize tacrolimus PK …

Background: The calcineurin inhibitor tacrolimus (Tac) is an integral part of the standard
immunosuppressive regimen after renal transplantation (RTx). However, clinical …

Tacrolimus, a calcineurin inhibitor, is a common immunosuppressant prescribed after organ
transplantation and has notable inter‐and intrapatient pharmacokinetic variability. The …

Older adults, the fastest growing population, represent almost 50% of all users of direct oral
anticoagulants (DOACs). Unfortunately, we have very little relevant pharmacological and …

Background Multiple clinical, demographic, and genetic factors affect the pharmacokinetics
of tacrolimus in children, yet in daily practice, a uniform body-weight based starting dose is …

Tacrolimus is an essential immunosuppressant for the prevention of rejection in solid organ
transplantation. Its low therapeutic index and high pharmacokinetic variability necessitates …

Different polymorphisms in genes encoding metabolizing enzymes and drug transporters
have been associated with tacrolimus pharmacokinetics. In particular, studies on CYP3A4 …